Annals of Clinical and Experimental NeurologyAnnals of Clinical and Experimental NeurologyАнналы клинической и экспериментальной неврологии2075-54732409-2533Eco-Vector126510.17816/ACEN.1265ReviewsОбзорыReview ArticlePotential biochemical markers of epilepsyПотенциальные биохимические маркеры эпилепсииhttps://orcid.org/0000-0002-7682-6672MaksimovaMarina Yu.МаксимоваМарина Юрьевна
Russian Federation

Dr. Sci (Med.), Prof., Head, 2nd Neurological department, Institute of Clinical and Preventive Neurology, Research Center of Neurology

д-р мед. наук, профессор, руководитель 2-го неврологического отделения Института клинической и профилактической неврологии

ncnmaximova@mail.ruhttps://orcid.org/0009-0009-7105-3103AbbasovaEkaterina M.АббасоваЕкатерина Мурадовна
Russian Federation

postgraduate student, 2nd Neurological department, Institute of Clinical and Preventive Neurology

аспирант 2-го неврологического отделения Института клинической и профилактической неврологии

ncnmaximova@mail.ruhttps://orcid.org/0000-0003-0787-6251ShitovaAnna D.ШитоваАнна Денисовна
Russian Federation

postgraduate student, 2nd Neurological department, Institute of Clinical and Preventive Neurology

аспирант 2-го неврологического отделения Института клинической и профилактической неврологии

ncnmaximova@mail.ruResearch Center of NeurologyНаучный центр неврологии1503202519162671701202531012025Copyright ©; 2025, Maksimova M.Y., Abbasova E.M., Shitova A.D.Copyright ©; 2025, Максимова М.Ю., Аббасова Е.М., Шитова А.Д.2025Maksimova M.Y., Abbasova E.M., Shitova A.D.Максимова М.Ю., Аббасова Е.М., Шитова А.Д.https://creativecommons.org/licenses/by/4.0https://annaly-nevrologii.com/pathID/article/view/1265

The diagnosis of epilepsy and assessment of the frequency and severity of seizures are essential for the treatment of patients. Epileptogenesis monitoring at different stages can be beneficial in assessing the efficacy of antiepileptic therapy. This approach relies on the concept of biomarkers. A subset of these biomarkers may possess not only diagnostic value but also prognostic value, which is defined as the ability to predict the nature of the epilepsy course and the probability of recurrent seizures.

Диагностика эпилепсии, оценка частоты и тяжести эпилептических приступов являются неотъемлемыми условиями лечения больных. Мониторинг эпилептогенеза на разных стадиях обеспечивает контроль эффективности противоэпилептической терапии. Базовым понятием такого подхода является категория биомаркеров, некоторые из них могут иметь, помимо диагностического, и прогностическое значение, которое заключается в возможности предсказать характер течения эпилепсии и вероятность возникновения повторных эпилептических приступов.

epileptogenesisbiomarkersepilepsyэпилептогенезбиомаркерыэпилепсияGovernment of the Russian FederationПравительство Российской ФедерацииDudek FE, Staley KJ. The time course and circuit mechanisms of acquired epileptogenesis. In: Noebels JL, Avoli M, Rogawski MA, et al., eds. Jasper’s basic mechanisms of the epilepsies. 4 th ed. Bethesda; 2012.Pitkänen A, Lukasiuk K, Dudek FE, Staley KJ. Epileptogenesis. Cold Spring Harb Perspect Med. 2015;5(10):a022822. DOI: 10.1101/cshperspect.a022822Ben-Ari Y. Epilepsies and neuronal plasticity: for better or for worse? Dialogues Clin Neurosci. 2008;10(1):17–27. DOI: 10.31887/DCNS.2008.10.1/ybenariPark KI. Understanding epileptogenesis from molecules to network alteration. Encephalitis. 2024;4(3):47–54. DOI: 10.47936/encephalitis.2024.00038Pitkänen A, Engel J Jr. Past and present definitions of epileptogenesis and its biomarkers. Neurotherapeutics. 2014;11(2):231–241. DOI: 10.1007/s13311-014-0257-2Devinsky O, Vezzani A, Najjar S, et al. Glia and epilepsy: excitability and inflammation. Trends Neurosci. 2013;36(3):174–184. DOI: 10.1016/j.tins.2012.11.008Kinboshi M, Ikeda A, Ohno Y. Role of astrocytic inwardly rectifying potassium (Kir) 4.1 channels in epileptogenesis. Front Neurol. 2020;11:626658. DOI: 10.3389/fneur.2020.626658Rana A, Musto AE. The role of inflammation in the development of epilepsy. J Neuroinflammation. 2018;15(1):144. DOI: 10.1186/s12974-018-1192-7Gautam V, Rawat K, Sandhu A, et al. An insight into crosstalk among multiple signaling pathways contributing to epileptogenesis. Eur J Pharmacol. 2021;910:174469. DOI: 10.1016/j.ejphar.2021.174469Bonosi L, Benigno UE, Musso S, et al. The role of aquaporins in epileptogenesis — a systematic review. Int J Mol Sci. 2023;24(15):11923. DOI: 10.3390/ijms241511923Gautam V, Rawat K, Sandhu A, et al. An insight into crosstalk among multiple signaling pathways contributing to epileptogenesis. Eur J Pharmacol. 2021;910:174469. DOI: 10.1016/j.ejphar.2021.174469Walker LE, Sills GJ, Jorgensen A, et al. High-mobility group box 1 as a predictive biomarker for drug-resistant epilepsy: a proof-of-concept study. Epilepsia. 2022;63(1):e1–e6. DOI: 10.1111/epi.17116Shen Y, Gong Y, Ruan Y, et al. Secondary epileptogenesis: common to see, but possible to treat? Front Neurol. 2021;12:747372. DOI: 10.3389/fneur.2021.747372Lee R, Feinbaum R, Ambros V. A short history of a short RNA. Cell. 2004;116(2 Suppl):S89–S92, 1 p following S96. DOI: 10.1016/s0092-8674(04)00035-2Henshall DC, Hamer HM, Pasterkamp RJ, et al. MicroRNAs in epilepsy: pathophysiology and clinical utility. Lancet Neurol. 2016;15(13):1368–1376. DOI: 10.1016/S1474-4422(16)30246-0Shaked I, Meerson A, Wolf Y, et al. MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase. Immunity. 2009;31(6):965–973. DOI: 10.1016/j.immuni.2009.09.019Cheng X, Ku CH, Siow RC. Regulation of the Nrf2 antioxidant pathway by microRNAs: new players in micromanaging redox homeostasis. Free Radic Biol Med. 2013;64:4–11. DOI: 10.1016/j.freeradbiomed.2013.07.025Wang J, Yu JT, Tan L, et al. Genome-wide circulating microRNA expression profiling indicates biomarkers for epilepsy. Sci Rep. 2015;5:9522. DOI: 10.1038/srep09522Wang X, Sun Y, Tan Z, et al. Serum MicroRNA-4521 is a potential biomarker for focal cortical dysplasia with refractory epilepsy. Neurochem Res. 2016;41(4):905–912. DOI: 10.1007/s11064-015-1773-0Salman MM, Sheilabi MA, Bhattacharyya D, et al. Transcriptome analysis suggests a role for the differential expression of cerebral aquaporins and the MAPK signalling pathway in human temporal lobe epilepsy. Eur J Neurosci. 2017;46(5):2121–2132. DOI: 10.1111/ejn.13652Manley GT, Binder DK, Papadopoulos MC, Verkman AS. New insights into water transport and edema in the central nervous system from phenotype analysis of aquaporin-4 null mice. Neuroscience. 2004;129(4):983–991. DOI: 10.1016/j.neuroscience.2004.06.088Kobylarek D, Iwanowski P, Lewandowska Z, et al. Advances in the potential biomarkers of epilepsy. Front Neurol. 2019;10:685. DOI: 10.3389/fneur.2019.00685Hol EM, Pekny M. Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system. Curr Opin Cell Biol. 2015;32:121–130. DOI: 10.1016/j.ceb.2015.02.004Yang Z, Wang KK. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 2015;38(6):364–374. DOI: 10.1016/j.tins.2015.04.003Wang Q, Lin Z, Yao C, et al. Meta-analysis of MMP-9 levels in the serum of patients with epilepsy. Front Neurosci. 2024;18:1296876. DOI: 10.3389/fnins.2024.1296876Bronisz E, Cudna A, Wierzbicka A, Kurkowska-Jastrzębska I. Serum proteins associated with blood-brain barrier as potential biomarkers for seizure prediction. Int J Mol Sci. 2022;23(23):14712. DOI: 10.3390/ijms232314712Meguid NA, Samir H, Bjørklund G, et al. Altered S100 calcium-binding protein B and Matrix Metallopeptidase 9 as biomarkers of mesial temporal lobe epilepsy with hippocampus sclerosis. J Mol Neurosci. 2018;66(4):482–491. DOI: 10.1007/s12031-018-1164-5Ichiyama T, Nishikawa M, Yoshitomi T, et al. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 in cerebrospinal fluid from children with prolonged febrile seizures. Comparison with acute encephalitis/encephalopathy. Neurology. 1998;50(2):407–411. DOI: 10.1212/wnl.50.2.407Iughetti L, Lucaccioni L, Fugetto F, et al. Brain-derived neurotrophic factor and epilepsy: a systematic review. Neuropeptides. 2018;72:23–29. DOI: 10.1016/j.npep.2018.09.005Shpak AA, Rider FK, Druzhkova TA, et al. Reduced levels of lacrimal glial cell line-derived neurotrophic factor (GDNF) in patients with focal epilepsy and focal epilepsy with comorbid depression: a biomarker candidate. Int J Mol Sci. 2023;24(23):16818. DOI: 10.3390/ijms242316818Zhao B, Shen LX, Ou YN, et al. Risk of seizures and subclinical epileptiform activity in patients with dementia: a systematic review and meta-analysis. Ageing Res Rev. 2021;72:101478. DOI: 10.1016/j.arr.2021.101478Ranasinghe KG, Kudo K, Hinkley L, et al. Neuronal synchrony abnormalities associated with subclinical epileptiform activity in early-onset Alzheimer’s disease. Brain. 2022;145(2):744–753. DOI: 10.1093/brain/awab442Martin SP, Leeman-Markowski BA. Proposed mechanisms of tau: relationships to traumatic brain injury, Alzheimer’s disease, and epilepsy. Front Neurol. 2024;14:1287545. DOI: 10.3389/fneur.2023.1287545Smith KM, Blessing MM, Parisi JE, et al. Tau deposition in young adults with drug-resistant focal epilepsy. Epilepsia. 2019;60(12):2398–2403. DOI: 10.1111/epi.16375Shapiro LA, Bialowas-McGoey LA, Whitaker-Azmitia PM. Effects of S100B on serotonergic plasticity and neuroinflammation in the hippocampus in down syndrome and Alzheimer’s disease: studies in an S100B overexpressing mouse model. Cardiovasc Psychiatry Neurol. 2010;2010:153657. DOI: 10.1155/2010/153657Meguid NA, Samir H, Bjørklund G, et al. Altered S100 calcium-binding protein B and matrix metallopeptidase 9 as biomarkers of mesial temporal lobe epilepsy with hippocampus sclerosis. J Mol Neurosci. 2018;66(4):482–491. DOI: 10.1007/s12031-018-1164-5Langeh U, Singh S. Targeting S100B Protein as a surrogate biomarker and its role in various neurological disorders. Curr Neuropharmacol. 2021;19(2):265–277. DOI: 10.2174/1570159X18666200729100427Abraira L, Santamarina E, Cazorla S, et al. Blood biomarkers predictive of epilepsy after an acute stroke event. Epilepsia. 2020;61(10):2244–2253. DOI: 10.1111/epi.16648Shi LM, Chen RJ, Zhang H, et al. Cerebrospinal fluid neuron specific enolase, interleukin-1β and erythropoietin concentrations in children after seizures. Childs Nerv Syst. 2017;33(5):805–811. DOI: 10.1007/s00381-017-3359-4Rabinowicz AL, Correale J, Boutros RB, et al. Neuron-specific enolase is increased after single seizures during inpatient video/EEG monitoring. Epilepsia. 1996;37(2):122–125. DOI: 10.1111/j.1528-1157.1996.tb00002.xCorreale J, Rabinowicz AL, Heck CN, et al. Status epilepticus increases CSF levels of neuron-specific enolase and alters the blood-brain barrier. Neurology. 1998;50(5):1388–1391. DOI: 10.1212/wnl.50.5.1388Willert C, Spitzer C, Kusserow S, Runge U. Serum neuron-specific enolase, prolactin, and creatine kinase after epileptic and psychogenic non-epileptic seizures. Acta Neurol Scand. 2004;109(5):318–323. DOI: 10.1046/j.1600-0404.2003.00232.xChang CC, Lui CC, Lee CC, et al. Clinical significance of serological biomarkers and neuropsychological performances in patients with temporal lobe epilepsy. BMC Neurol. 2012;12:15. DOI: 10.1186/1471-2377-12-15Yasak IH, Yilmaz M, GÖnen M, et al. Evaluation of ubiquitin C-terminal hydrolase-L1 enzyme levels in patients with epilepsy. Arq Neuropsiquiatr. 2020;78(7):424–429. DOI: 10.1590/0004-282x20200040Mondello S, Palmio J, Streeter J, et al. Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) is increased in cerebrospinal fluid and plasma of patients after epileptic seizure. BMC Neurol. 2012;12:85. DOI: 10.1186/1471-2377-12-85Li Y, Wang Z, Zhang B, et al. Cerebrospinal fluid ubiquitin C-terminal hydrolase as a novel marker of neuronal damage after epileptic seizure. Epilepsy Res. 2013;103(2-3):205–210. DOI: 10.1016/j.eplepsyres.2012.08.001Tikhonova MA, Shvaikovskaya AA, Zhanaeva SY, et al. Concordance between the in vivo content of neurospecific proteins (BDNF, NSE, VILIP-1, S100B) in the hippocampus and blood in patients with epilepsy. Int J Mol Sci. 2023;25(1):502. DOI: 10.3390/ijms25010502Tan Z, Jiang J, Tian F, et al. Serum Visinin-like protein 1 is a better biomarker than Neuron-specific enolase for seizure-induced neuronal injury: a prospective and observational study. Front Neurol. 2020;11:567587. DOI: 10.3389/fneur.2020.567587